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Protocol
AbstrACt
Introduction Carotid intima-media thickness (CIMT) 
is a surrogate marker of atherosclerosis that is 
measured in adults and children to better understand 
the natural history of cardiovascular disease (CVD). In 
adults, CIMT is predictive of myocardial infarction and 
stroke. In children and adolescents, CIMT is used to 
assess vascular changes in the presence of CVD risk 
factors (obesity, hypertension, smoking, etc) or clinical 
conditions associated with a high risk for premature 
CVD. However, there is no comprehensive overview, 
in a life-course epidemiology perspective, of the risk 
factors and determinants of CIMT in children. It is also 
important to evaluate between-study differences in CIMT 
measurement methods and take them into consideration 
when drawing conclusions. Our objective is to 
systematically review the evidence on the relationship 
between CIMT and prenatal and postnatal exposures or 
interventions in children, as well as documenting and 
discussing the CIMT measurement methods.
Methods and analysis Systematic searches of the 
Medical Literature Analysis and Retrieval System Online 
(MEDLINE), Excerpta Medica (EMBASE)and Central 
Register of Controlled Trials (CENTRAL) databases 
will be conducted. The reference lists and other 
literatures sources will be browsed. Observational 
and experimental studies in children from birth up 
to 18 years will be included. Prenatal and postnatal 
exposures or interventions assessed in relationship 
with CIMT will be considered for inclusion. Examples 
might include gestational age, obesity, hypertension, 
tobacco exposure, specific at-risk conditions (chronic 
kidney disease, diabetes, etc) or statin treatment. The 
outcome will be CIMT assessed by ultrasonography. 
The setting, scanning and measurement methods for 
each included study will be described in detail. Results 
will be synthesised descriptively and, if appropriate, 
will be pooled across studies to perform meta-
analyses. Separate meta-analyses for each exposure or 
intervention type will be conducted.
Ethics and dissemination This systematic review will 
be published in a peer-reviewed journal. A report will be 
prepared for clinicians and other healthcare decision-
makers.
PrOsPErO registration number CRD42017075169.
IntrOduCtIOn
rationale
Ultrasound carotid intima-media thickness 
(CIMT) is a non-invasive technique that is 
used in adult and paediatric populations for 
the assessment of subclinical cardiovascular 
disease (CVD) and as a surrogate end point 
for treatment efficacy in research settings.1–4 
Ultrasound CIMT correlates well with its 
histological measurement5 and coronary 
atherosclerosis.6 It has been argued, however, 
that elevated CIMT is not always equivalent to 
subclinical atherosclerosis. At lower degrees 
of thickness and at early ages, it may repre-
sent hypertrophy of the intimal and medial 
layers in the absence of true atherosclerotic 
lesions.7 8 Nevertheless, increased CIMT as an 
adaptive response to blood flow, intraluminal 
pressure or other biological factors relates 
to the known pathophysiology of atheroscle-
rosis.9 10 
In adults, CIMT is associated with tradi-
tional CVD risk factors11 and is predictive 
of heart attack and stroke.1 12–17 Longitu-
dinal studies showed that elevated CIMT in 
strengths and limitations of this study
 ► A critical review of the methodology of the studies 
and the carotid intima-media thickness measure-
ment methods will be included.
 ► Most evidence for this systematic review is expect-
ed to derive from observational studies, thus limiting 
our ability to assess causal relationships, yet facili-
tating the generalisability of findings across different 
populations and settings.
 ► The review methods were carefully planned accord-
ing to current guidelines and prospectively regis-
tered with the  International Prospective Register of 
Systematic Reviews (PROSPERO) in order to mini-
mise risk of bias related to study design and con-
duct, or reporting of results in the completed review.
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adulthood is linked to risk factors in childhood,18 such 
as obesity, high serum cholesterol and insulin levels.19–21 
In children, several studies assessed CIMT and its rela-
tion with risk factors such as obesity,22 23 dyslipidaemia,3 24 
elevated blood pressure25 26 or smoking.27 CIMT was also 
used to assess CVD risk in paediatric patients with clinical 
conditions that are associated with accelerated atheroscle-
rosis, for instance, diabetes or chronic kidney disease.28–34 
Clinical trials in children and adolescents showed a 
decrease in CIMT following interventions to control risk 
factors.35 36 Furthermore, there is growing evidence that 
prenatal factors are also determinants of cardiovascular 
health across the life course and may have an effect on 
CIMT.37 38 These data provide support for CIMT as a 
marker of vascular remodelling in youth. However, it 
remains to be determined among which children CIMT 
is increased and if it is clinically relevant to measure 
it.39 Further, a comprehensive overview, in a life-course 
epidemiology perspective,40 of the prenatal and postnatal 
factors associated with CIMT in children is lacking.
The heterogeneity in CIMT measurement methods 
requires careful consideration as several methodolog-
ical aspects related to the site of measurement, the edge 
detection approach and ultrasound settings, or the 
training level of the operators influence the quality and 
interpretation of results.9 41–43 Standardised equipment 
and imaging protocols, as well as sonographers’ high 
expertise, are essential for CIMT acquisition and anal-
ysis.42 44 Also, the technique can be challenging, especially 
in young children, depending on the patient’s compli-
ance and anatomic particularities.39 Still, our research 
group proved that CIMT assessment is feasible and 
reproducible in non-sedated infants.45 Due to differences 
in CIMT measurement technique, the between-study 
comparability is commonly considered to be limited. 
Nevertheless, a formal evaluation of the CIMT measure-
ment methods in children is needed for further clarifica-
tion of this limitation.
Objectives
Therefore, our objective is to systematically review the 
evidence on the relationship between CIMT and prenatal 
and postnatal exposures or interventions in children 
from birth up to 18 years, as well as documenting and 
discussing the CIMT measurement methods.
MEthOds And AnAlysIs
The protocol has been developed according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statements,46–48 the Meta-anal-
ysis of Observational Studies in Epidemiology (MOOSE) 
guidelines49 and following methods outlined in the 
Cochrane Handbook for Systematic Reviews of Interventions.50 
This systematic review has been registered with the Inter-
national Prospective Register of Systematic Reviews (regis-
tration number CRD42017075169).
Eligibility criteria
Study designs
Observational and experimental primary research 
studies will be eligible. The following study designs will 
be considered: cohort, case–control and cross-sectional 
studies; randomised and non-randomised, controlled 
and non-controlled trials; quasi-experimental studies. 
Case reports, case series, opinion papers, letters to the 
editor, comments, conference proceedings, policy papers, 
reviews and meta-analyses, study protocols without base-
line data and animal studies will be excluded.
Participants
We will include studies in children from birth up to 
18 years. Studies with both children and adults will be 
included if the data for children can be extracted sepa-
rately. Both apparently healthy children and subjects with 
clinical conditions will be included.
Exposures/interventions
There will be no restrictions regarding the types of expo-
sures or interventions considered in the primary studies. 
Prenatal and postnatal exposures, at the individual or envi-
ronmental level, will be considered for inclusion. Exam-
ples might include gestational age, birth weight, maternal 
gestational diabetes, traditional CVD risk factors (blood 
pressure, blood lipids, etc), specific at-risk clinical condi-
tions (chronic kidney disease, diabetes mellitus, familial 
hypercholesterolemia, HIV infection, chronic inflamma-
tory disease, etc) or tobacco exposure. For experimental 
studies, we will consider both pharmacological and 
non-pharmacological interventions (eg, interventions 
to promote physical activity or smoking cessation, treat-
ments with antihypertensive or lipid-lowering drugs).
Comparators
Studies assessing specific clinical conditions in relation-
ship with CIMT will be included provided they use a 
control group without the clinical condition of interest.
Outcome measures
The outcome will be the intima-media thickness of the 
carotid artery measured by ultrasonography.
Time frame
There will be no restriction by duration of intervention or 
by length of follow-up.
Setting
There will be no restriction by type of setting.
Language
Studies in English and French will be included.
search strategy
Systematic searches will be conducted in the following 
databases: (1) Medical Literature Analysis and Retrieval 
System Online (MEDLINE) from 1946 onwards 
(PubMed interface); (2) Excerpta Medica database 
(EMBASE) from 1947 to present (via http:// embase. 
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com); and (3) Cochrane Central Register of Controlled 
Trials (CENTRAL) from 1947 onwards (Wiley interface). 
The search strategy structures for these databases were 
reviewed and refined by two experienced librarians. They 
were constructed to include the two main concepts of 
this systematic review: (1) children and adolescents and 
(2) CIMT. The search strategy for MEDLINE (Box 1) was 
created first and then adapted for the other two data-
bases (supplementary appendix 1 and 2  in the online 
supplementary material file). The reference lists of the 
retrieved articles and other reviews in the field will be 
browsed to identify further studies of interest. Supple-
mentary searches will be conducted on Web of Science 
and Google Scholar. To identify unpublished or ongoing 
studies, we will search the following registers: the  Clini-
calTrials. gov (http://www. clinicaltrials. gov), the EU Clin-
ical Trials Register (http://www. clin ical tria lsre gister. eu) 
and the International Clinical Trials Registry Platform 
(http://www. isrctn. com). The principal investigators of 
completed studies found on these trial registers will be 
contacted, via email, to access unpublished data.
study selection
An initial evaluation of the collection of articles will be 
performed to eliminate duplicate publications. Studies 
will be assessed for inclusion against prespecified criteria 
independently and in parallel by two reviewers (AME and 
ML). This process will be conducted in two stages, initially 
on the basis of titles and abstracts and then by reviewing 
the full text of the articles retained in the first step. Any 
disagreements between the two reviewers will be solved 
by discussion. If consensus is not reached, arbitration 
by a third reviewer (AC) will be required. The decisions 
made for each article will be recorded. The systematic 
reviews software Covidence (Veritas Health Innovation, 
Melbourne, Australia; http://www. covidence. org) will be 
used to manage the study selection process.
data extraction
Data will be extracted independently by two reviewers 
(AME and ML) using an electronic database created 
in Microsoft Office Excel 2007. Disagreements will be 
resolved by discussion or, if necessary, with the arbitration 
of a third reviewer (AC). Drop-down lists will be created 
whenever appropriate to minimise errors. Calibration 
exercises will be conducted before this review stage to 
enhance consistency between assessors. Two members of 
the review team (ML and AC) have previous experience 
in study quality appraisal and data collection for system-
atic reviews.51–54
The following data items will be extracted:
1. Study identification: authors, publication year, journal, 
funding or sponsorship.
2. Study characteristics: study type (observational or ex-
perimental), study design, country, sampling proce-
dure, sample size, study setting, study duration or peri-
od of follow-up, participation rates.
3. Study subjects characteristics: inclusion and exclusion 
criteria, age, sex, ethnicity, anthropometric measures; 
we will also extract data on medication/co-interven-
tions and comorbidities in children with clinical con-
ditions.
4. Exposures or interventions:
 – Exposure type and its characteristics (definition and 
cut-offs, measurement method, follow-up period/
duration of exposure).
 – Intervention type and its characteristics (dosage/in-
tensity, frequency, duration, personnel who deliver 
it, etc).
5. Outcome:
 – CIMT definition and additional features of the 
CIMT measurement method (Box 2), number of 
measurements.
6. Potential confounding and effect modifiers:
 – Confounding factors and effect modifiers consid-
ered in the primary studies, depending on the expo-
box 1 search strategy for Medical literature Analysis 
and retrieval system Online (MEdlInE)
1. baby[tiab] OR babies[tiab] OR preterm*[tiab] OR pre-term*[tiab] OR 
prematur*[tiab] OR newborn*[tiab] OR infan*[tiab] OR infant[mh] 
OR toddler*[tiab] OR kindergart*[tiab] OR kid[tiab] OR kids[tiab] OR 
boy*[tiab] OR girl*[tiab] OR preschool*[tiab] OR pre-school*[tiab] 
OR child*[tiab] OR child[mh] OR school*[tiab] OR preteen*[tiab] 
OR prepube*[tiab] OR preadolescen*[tiab] OR highschool*[tiab] 
OR high-school*[tiab] OR student*[tiab] OR adolescen*[tiab] OR 
adolescent[mh] OR teen*[tiab] OR pube*[tiab] OR youngster*[tiab] 
OR youth*[tiab] OR pediatric*[tiab] OR paediatric*[tiab] OR peadi-
atric*[tiab] OR pediatrics[mh] OR neonat*[tiab] OR perinat*[tiab] OR 
offspring[tiab] OR descendant*[tiab] 
2.  “intima media thickness”[tiab] OR “intima media thickening”[tiab] 
OR “intimal medial thickness”[tiab] OR “intimal medial thicken-
ing”[tiab] OR “intimal media thickness”[tiab] OR “intimal media 
thickening”[tiab] OR “intima medial thickness”[tiab] OR “intima 
medial thickening”[tiab] OR “intima media complex”[tiab] OR 
“intimal medial complex”[tiab] OR “intimal media complex”[tiab] 
OR “intimamedia thickness”[tiab] OR “wall thickness”[tiab] OR 
“wall thickening”[tiab] OR “arterial thickness”[tiab] OR “artery 
thickness”[tiab] OR “artery wall thickness”[tiab] OR “arterial wall 
thickness”[tiab] OR “intimal thickening”[tiab] OR “tunica intima/di-
agnostic imaging”[mh] OR “tunica media/diagnostic imaging”[mh] 
3.  carotid[tiab] OR “arteria carotis”[tiab] OR “carotid arteries”[mh] 
OR “carotid artery diseases”[mh:noexp] 
4.  atherosclero*[tiab] OR atherosclerosis[mh] OR arteriosclero*[tiab] 
OR arteriosclerosis[mh] OR “end organ damage”[tiab] OR “target 
organ damage”[tiab] OR “cardiovascular diseases”[mh:noexp] 
5.  ultrasound[tiab] OR echograph*[tiab] OR ultrasonograph*[tiab] OR 
sonograph*[tiab] OR ultrasonography[mh] 
6.  #2 AND #3 
7.  #3 AND #4 AND #5 
8.  “carotid intima-media thickness”[mh] OR “carotid arteries/diag-
nostic imaging”[mh] 
9.  #6 OR #7 OR #8 
10.  #1 AND #9 
11.  #10 NOT (animals[mh] NOT humans[mh]) 
mh, Medical Subject Headings terms; tiab, title/abstract.  
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sure or intervention of interest, will be documented 
and taken into account when performing data anal-
ysis (eg, gestational age, birth weight, blood pres-
sure, blood lipids, blood glucose, tobacco exposure, 
family history of CVD, physical activity or sedentary 
behaviour).
 – Adjusted and unadjusted measures of effect or asso-
ciation will be recorded.
We will collate information provided in multiple reports 
of the same study if they aim to assess the same exposure/
intervention. If their aim is to assess different exposures/
interventions, multiple reports of the same study will be 
considered separately in this systematic review. When 
CIMT measurements are available at several time points, 
the time point closest to the end of the intervention or 
the follow-up period will be selected for data extraction. 
When essential information is missing from the published 
reports, we will contact the authors of the original studies 
by email to access missing data. A maximum of three 
email attempts per study will be undertaken.
study quality
Quality appraisal will be performed independently by 
two reviewers (AME and ML). Any disagreements will 
be solved by discussion or, if necessary, with the arbi-
tration of a third reviewer (AC). Quality assessment of 
experimental studies will be conducted in line with the 
Cochrane collaboration’s risk of bias tool.50 Observational 
studies will be evaluated using the Newcastle-Ottawa Scale 
for non-randomised studies.55
The reliability of the CIMT measurement methods 
used in primary studies will be evaluated following a 
predefined tool developed for the current review based 
on existing standards,9 39 41 42 56 57 and with input from the 
review team members with expertise in CIMT measure-
ment (YM, SDB, NS). The following three domains 
will be appraised: (1) site of measurement, (2) image 
analysis methods and (3) assessment of reproducibility. 
The complete tool and the algorithm of judgement are 
presented in the online supplementary appendix 3.
data analysis
The following software programs will be used to carry out 
statistical analyses: RStudio (V.0.99.473), Stata (V.14.1) 
and RevMan (V.5.3) (Copenhagen: The Nordic Cochrane 
Centre, 2014).
Measures of effect or association
For experimental studies, the measure of effect for contin-
uous outcomes will be the difference in means between 
the intervention and the control groups. For categorical 
outcomes, the measure of effect will be the OR or the 
relative risk. For observational studies, the measure of 
association for continuous outcomes will be the correla-
tion or regression coefficient, or the difference in means 
between the exposure and the control groups. For cate-
gorical outcomes, the measure of association will be the 
OR at different exposure levels.
Descriptive analyses
The characteristics of the study population and details 
about the CIMT measurement methods reported in 
each study will be presented in text and tables. We 
will also perform a descriptive analysis of studies: (1) 
not providing sufficient data to be included in the 
meta-analyses and (2) reporting results in a format 
that cannot be converted to a standard metric and/or 
common effect size measure.
Meta-analyses
If possible, we will pool results across studies for each 
type of exposure or intervention. This will be conducted 
separately for observational and experimental studies. 
Meta-analyses will be computed using random-effects 
models as heterogeneity is expected.58 Results will be 
presented graphically through forest plots. If studies are 
not sufficiently homogenous to be combined in a quanti-
tative synthesis, their results will be presented in a narra-
tive format or in graphical displays having the pooled 
estimate suppressed.50 The comparability of studies will 
be judged based on the CIMT definition and the clinical 
characteristics of the studied population.
Assessment of heterogeneity
Statistical heterogeneity will be evaluated using the 
Cochran’s Q test and will be quantified using the I2 
method.50 If sufficient studies are available, the sources 
of variability will be investigated by means of subgroup 
analyses accompanied by interaction tests and meta-re-
gression based on the following variables:
box 2 Carotid intima-media thickness (CIMt)  
characteristics
Equipment
 ► Ultrasound device type 
 ►  Ultrasound settings: imaging technique (eg, B-mode, M-mode), 
transducer (array, frequency) 
 ►  Cardiac cycle tracking method (eg, electrocardiography, other) 
 ►  Data storage facilities 
Image acquisition and analysis
 ► Side (right, left, combination), segment (common carotid artery, in-
ternal carotid artery, carotid bifurcation, combination), wall (far-wall, 
near-wall, combination), angle of insonation 
 ►  Atherosclerotic plaque (inclusion or exclusion of plaque, definition 
of plaque) 
 ►  Type of measurement (eg, manual, semiautomatic or automatic) 
 ►  Timing during the cardiac cycle (eg, irrespective of the cardiac cy-
cle, end-diastole, other) 
 ►  Segmental calculation (ie, mean or maximum CIMT)
Quality control procedures
 ► Use of a predefined standardised imaging protocol, training level of 
operators, type and number of operators (sonographers, readers) 
 ►  Assessment of reproducibility of measurements (ie, intraoperator 
and/or interoperator variability indices) 
 ►  Any other quality control measures taken (eg, phantom scans, 
maintenance routine of the equipment) 
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 ► Study design, study setting, duration of intervention 
or duration of exposure/follow-up.
 ► Sample characteristics: sample size, age, sex.
 ► Properties of the CIMT measurement method: 
far-wall versus near-wall or combination of walls, one 
side versus both sides, manual versus semiautomatic/
automatic measurements, transducer frequency.
Sensitivity analyses will be carried out by (1) excluding 
relatively small studies, (2) excluding studies of low 
quality and (3) restricting analyses to studies having the 
end point defined as mean CIMT.
Assessment of publication bias
Publication bias will be assessed by visual inspection of 
funnel plots, and, if sufficient studies will be available, 
funnel plot asymmetry will be examined using the Egger’s 
test.50 59
Assessment of strength of evidence
The Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) framework will be applied 
in order to assess the strength of the body of evidence for 
this systematic review.60
Patient and public involvement
This is a protocol for a systematic review and there was 
no patient or public involvement in framing the research 
objective or study design. 
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